1. Home
  2. CLDX vs MSDL Comparison

CLDX vs MSDL Comparison

Compare CLDX & MSDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CLDX
  • MSDL
  • Stock Information
  • Founded
  • CLDX 1983
  • MSDL 2019
  • Country
  • CLDX United States
  • MSDL United States
  • Employees
  • CLDX N/A
  • MSDL N/A
  • Industry
  • CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • MSDL
  • Sector
  • CLDX Health Care
  • MSDL
  • Exchange
  • CLDX Nasdaq
  • MSDL NYSE
  • Market Cap
  • CLDX 1.6B
  • MSDL 1.9B
  • IPO Year
  • CLDX 2008
  • MSDL N/A
  • Fundamental
  • Price
  • CLDX $23.78
  • MSDL $21.45
  • Analyst Decision
  • CLDX Buy
  • MSDL Buy
  • Analyst Count
  • CLDX 7
  • MSDL 7
  • Target Price
  • CLDX $64.83
  • MSDL $21.67
  • AVG Volume (30 Days)
  • CLDX 1.1M
  • MSDL 354.2K
  • Earning Date
  • CLDX 02-24-2025
  • MSDL 01-01-0001
  • Dividend Yield
  • CLDX N/A
  • MSDL 9.33%
  • EPS Growth
  • CLDX N/A
  • MSDL N/A
  • EPS
  • CLDX N/A
  • MSDL N/A
  • Revenue
  • CLDX $9,976,000.00
  • MSDL N/A
  • Revenue This Year
  • CLDX N/A
  • MSDL $1,597.39
  • Revenue Next Year
  • CLDX N/A
  • MSDL $15.28
  • P/E Ratio
  • CLDX N/A
  • MSDL N/A
  • Revenue Growth
  • CLDX 128.55
  • MSDL N/A
  • 52 Week Low
  • CLDX $22.17
  • MSDL $19.05
  • 52 Week High
  • CLDX $53.18
  • MSDL $24.18
  • Technical
  • Relative Strength Index (RSI)
  • CLDX 41.99
  • MSDL 60.46
  • Support Level
  • CLDX $22.17
  • MSDL $20.23
  • Resistance Level
  • CLDX $29.05
  • MSDL $21.17
  • Average True Range (ATR)
  • CLDX 1.57
  • MSDL 0.36
  • MACD
  • CLDX -0.26
  • MSDL 0.05
  • Stochastic Oscillator
  • CLDX 23.40
  • MSDL 90.48

About CLDX Celldex Therapeutics Inc.

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

About MSDL MORGAN STANLEY DIRECT LENDING FUND

Morgan Stanley Direct Lending Fund is a fund whose investment objective is to achieve attractive risk-adjusted returns via current income and, to a lesser extent, capital appreciation by investing predominantly in directly originated senior secured term loans issued by U.S. middle-market companies backed by private equity sponsors. It invests predominantly in directly originated senior secured term loans including first lien senior secured term loans including unitranche loans and second lien senior secured term loans, with the balance of the investments expected to be in higher-yielding assets such as mezzanine debt, unsecured debt, equity investments and other opportunistic asset purchases.

Share on Social Networks: